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As liposomes are cleared from the circulation to a substantial extent by the phagocytic cells of the mono-
nuclear phagocyte system (MPS), there is a question whether administration of liposome-based therapeutic
agents interferes with clearance of infectious organisms by the MPS from blood. In the present study, at first
the effect of administration of three types of empty liposomes (devoid of drug), differing in blood residence time,
on carbon clearance and bacterial clearance from blood was studied with mice. Classical liposomes (LIP A)
and placebo liposomes with lipid composition as in AmBisome (LIP B) or as in Doxil (LIP C) were used. Li-
posomes were administered intravenously as a single dose. Second, the effect of multiple-dose administration
of AmBisome on bacterial blood clearance was studied with rats. AmBisome was administered with two dif-
ferent dosage schedules. The blood clearance capacity of the MPS was monitored at different time points after
the last liposome injection. It was shown that the carbon blood clearance capacity of the MPS was impaired
only at a high lipid dose of empty classical liposomes. The bacterial blood clearance capacity was never
impaired, not even after prolonged treatment with AmBisome administered in a clinically relevant regimen.
The therapeutic value of liposomes as drug carriers, in par-
ticular for anticancer, antifungal, and antibacterial agents, has
been demonstrated by a substantial number of research groups.
Quite recently, various pharmaceutical companies have suc-
ceeded in scaling up the production of various liposome-based
therapeutic agents, allowing clinical application. Patients treat-
ed with liposomal agents are often severely immunocompro-
mised and hence highly susceptible to developing systemic
infections. Especially in these immunocompromised patients,
the resident phagocytic cells of the mononuclear phagocyte
system (MPS) play a major role in the clearance of microor-
ganisms from the blood. Malfunction of the MPS may result in
generalization of the infection and hence increased mortality.
Liposomes are also cleared from the circulation by the pha-
gocytic cells of the MPS in liver (Kupffer cells) and spleen (14).
The question arises whether intravenous (i.v.) administration
of liposomes interferes with the clearance of infectious organ-
isms from the blood. During circulation of liposomes, binding
of blood proteins to liposomes (6, 18) might lead to reduced
opsonization and clearance of microorganisms, whereas after
MPS uptake of liposomes saturation of the phagocytic uptake
capacity might be expected (14). Particularly when potentially
toxic agents are encapsulated in liposomes, as is the case for
the liposomal formulations used in clinical practice, serious
damage of the MPS due to release of the entrapped drug with-
in the phagocytic cells should be taken into consideration.
It was previously demonstrated in rats that administration of
liposomes that rapidly accumulate in the MPS (classical lipo-
somes) and contain the chemotherapeutic agent doxorubicin
(DOX) can result in toxicity towards liver macrophages in
terms of impaired phagocytic functions or even depletion of
liver macrophages (7). Progress in liposome technology has
yielded new types of liposomes that are substantially able to
avoid uptake by the MPS and therefore exhibit a relatively
long residence time in blood (26). The industrially prepared
liposome formulations AmBisome (NeXstar Pharmaceuti-
cals, Inc., San Dimas, Calif.) and Doxil (Sequus Pharmaceuti-
cals, Inc.) indeed show relatively long blood circulation times,
although MPS uptake to a certain extent is still observed. As
these liposomes carry the potentially toxic agents amphotericin
B (AMB) and DOX, respectively, possible implications of i.v.
administration of these liposome formulations regarding blood
clearance capacity of the MPS need to be investigated thor-
oughly. It was recently shown by Daemen et al. (9) that DOX
encapsulated in long-circulating liposomes was less toxic for
the liver macrophage population than was DOX encapsulated
in classical liposomes (7). With Doxil, a DOX-containing lipo-
some that shows even more prolonged circulation in blood,
MPS toxicity in terms of decreased bacterial blood clearance
was not observed, provided that Doxil was administered at
clinically relevant intervals (21).
In the present study, the effects of single-dose administration
of three types of empty liposomes (devoid of drug), differing in
blood residence time, on carbon clearance and bacterial clear-
ance from blood were investigated with mice. The classical
parameter for the determination of the phagocytic capacity of
the MPS is the clearance of carbon particles from blood. From
a clinical point of view, measuring the clearance of bacteria
from blood after liposomal administration seems to be much
more relevant. As there are no previous reports on the effects
of administration of empty liposomes on bacterial blood clear-
ance, we have chosen to determine bacterial blood clearance
under experimental conditions similar to those described for
carbon clearance (1, 10, 11) to enable a direct comparison in
one study.
In a second series of experiments, the effects of AmBisome
given in multiple-dose schedules on bacterial clearance from
blood were studied with rats, by a method that had been pre-
viously described for measuring the toxicity of DOX-contain-
ing liposomes (7, 9, 21).
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MATERIALS AND METHODS
Animals. Female BALB/c mice (10 to 13 weeks old, specified pathogen free)
were obtained from Iffa Credo (L’Arbresle, France). Female R-strain albino rats
(20 to 25 weeks old, specified pathogen free) were obtained from Harlan CPB
(Austerlitz, The Netherlands).
Bacteria. Klebsiella pneumoniae (capsular serotype 2; ATCC 43816) and Staph-
ylococcus aureus (clinical isolate) were used.
Materials. Egg phosphatidylcholine, phosphatidylserine (PS), hydrogenated
soybean phosphatidylcholine (HSPC), distearoylphosphatidylglycerol (DSPG),
and polyethylene glycol (PEG) 1900 derivative of distearoylphosphatidyletha-
nolamine (PEG-DSPE) were obtained from Avanti Polar Lipids, Inc. (Alabaster,
Ala.). Cholesterol (Chol) was from Sigma (St. Louis, Mo.). Chloroform, meth-
anol, and tert-butanol were from Merck (Darmstadt, Germany). Deferoxamine
mesylate (DF) was from Ciba-Geigy (Basel, Switzerland). 67Ga-citrate was from
Nordian (Montreal, Canada). Carbon (drawing ink FT) was from Pelikan AG
(Hannover, Germany). Lysis buffer (Isolator 10 blood culture system) was from
Wampol Laboratories (Cranbury, N.J.). Tryptone soy agar was from Unipath Ltd
(Basingstoke, United Kingdom).
Liposomes. For the clearance studies with mice, three different types of empty
liposomes were prepared at our laboratory. Classical liposomes (LIP A), with an
average particle size of 300 nm, consisted of egg phosphatidylcholine, PS, and
Chol in a molar ratio of 40:10:50; placebo liposomes with lipid composition as in
AmBisome (LIP B), with an average particle size of 100 nm, consisted of HSPC,
DSPG, and Chol in a molar ratio of 100:40:50; placebo liposomes with lipid
composition as in Doxil (LIP C), with an average particle size of 100 nm,
consisted of HSPC, PEG-DSPE, and Chol in a molar ratio of 73.5:7:50. Lipo-
somes were prepared in our laboratory as previously described (4, 5, 24). In
short, for LIP A and LIP C the lipid mixture in chloroform-methanol was
evaporated to dryness in a round-bottom flask, redissolved in tert-butanol, and
lyophilized. The lipid film was hydrated with HEPES buffer (10 mM HEPES, 150
mM NaCl, pH 7.4). For LIP B, the lipid mixture in chloroform-methanol was
evaporated to dryness and directly hydrated with buffer containing 10 mM
sodium succinate and 10% (wt/vol) sucrose (pH 5.5). The liposome suspension
was either extruded through polycarbonate filters (LIP A) or sonicated (LIP B
and LIP C). Mean particle size was determined by dynamic light scattering
(Malvern 4700 system; Malvern, United Kingdom). Phospholipid concentration
was determined by a phosphate assay (2).
For the clearance studies with rats, AmBisome was kindly provided by
NeXstar Pharmaceuticals, Inc. AmBisome, AMB encapsulated in small unila-
mellar vesicles (80 nm) consisting of HSPC, DSPG, and Chol in a molar ratio of
100:40:50, was provided as a lyophilized preparation. The powder was reconsti-
tuted according to the manufacturer’s instructions to give a liposomal suspension
containing 4 g of AMB per liter and 35 g of lipid per liter.
Determination of the time points at which 50% or 10% of injected empty
liposome is present in the blood of mice. The residence time of liposomes in
blood was determined with liposomes radiolabeled with a 67Ga-DF complex
(67Ga-DF) in the aqueous interior of the liposomes, as described by Woodle
(25). As shown by Gabizon et al. (12), this 67Ga-DF complex is appropriate for
in vivo tracing of intact liposomes because of advantages of minimal transloca-
tion of radioactive label to plasma proteins and the high renal clearance rate
when the label is released from the liposomes extracellularly. Radiolabeled
liposomes were administered i.v. as a single dose in mice at either 400 mmol of
lipid/kg of body weight (LIP A, LIP B, and LIP C) or 80 mmol of lipid/kg (LIP
A only). At various time points after administration, 200 ml of blood was col-
lected from the mice in heparinized tubes by retro-orbital bleeding under CO2
anesthesia. Blood samples as well as the injected dosage of liposomes were
assayed for 67Ga-DF in a gamma counter (Minaxy 5530; Packard Instruments,
Downers Grove, Ill.).
Monitoring of carbon clearance or bacterial clearance from blood in mice
treated with empty liposomes. Liposomes were injected i.v. into mice at a single
dose of either 400 mmol of total lipid/kg (LIP A, LIP B, and LIP C) or 80 mmol
of total lipid/kg (LIP A only). At different time points after administration of
liposomes or buffer (controls), i.e., at 1 min after liposome administration
(.90% of liposomes present in blood) and at the times that 50 or 10% of
liposomes were present in blood, the blood clearance capacity of the MPS was
determined for six mice per time point per treatment. Carbon clearance was
monitored by i.v. injection of carbon diluted in phosphate-buffered saline at a
dose of 1 mg/mouse. At 1 and 10 min after carbon administration, blood was
collected by retro-orbital bleeding under CO2 anesthesia, and blood carbon
concentration was determined, after lysis of blood cells with lysis buffer. The
percentage of clearance within 9 min was calculated. Bacterial clearance was
monitored by i.v. injection of K. pneumoniae at an inoculum of 1.4 3 105
bacteria/kg or S. aureus at an inoculum of 1.4 3 109 bacteria/kg. At 1 and 10 min
after bacterial inoculation, blood was collected and from this the number of
viable bacteria was determined, after lysis of blood cells. The number of viable
bacteria was determined by making plate counts of 10-fold serial dilutions of the
blood samples on tryptone soy agar.
Monitoring of bacterial clearance from blood in rats treated with AmBisome.
AmBisome was administered i.v. to rats for either 5 or 10 consecutive doses of
5 mg of AMB/kg (equivalent to 50 mmol of lipid/kg) at 24-h intervals. At two
different time points after administration, i.e., 24 and 72 h after the last dose,
bacterial blood clearance was determined. Bacterial clearance was monitored for
10 rats per time point per treatment group by i.v. injection of K. pneumoniae at
an inoculum of 3.2 3 107 bacteria/kg; at 60 and 120 min after bacterial inocu-
lation, blood was collected and from this the number of viable bacteria was
determined.
Statistical analysis. In the study with empty liposomes, results were expressed
as the mean percentages of clearance within 9 min. In the study with AmBisome,
results were expressed as the geometric means of numbers of viable bacteria in
blood at various time points. In both studies, differences in blood clearance
between the various treatment groups were analyzed by the Mann-Whitney test.
FIG. 1. Residence of 67Ga-DF-labeled liposomes in blood after single-dose
administration (i.v.) in mice. Only the time points at which .90, 50, or 10% of
injected liposomes are present in blood are indicated (n 5 3 per time point). E,
LIP A (classical liposomes) at 80 mmol of lipid/kg; F, LIP A at 400 mmol of
lipid/kg; n, LIP B (placebo liposomes with lipid composition as in AmBisome) at
400 mmol of lipid/kg; , LIP C (placebo liposomes with lipid composition as in
Doxil) at 400 mmol of lipid/kg.
FIG. 2. Clearance of carbon from blood in mice after single-dose administration (i.v.) of empty liposomes at 400 mmol of lipid/kg. LIP A, classical liposomes; LIP
B, placebo liposomes with lipid composition as in AmBisome; LIP C, placebo liposomes with lipid composition as in Doxil. Carbon clearance from blood was
determined at the time that .90% (a), 50% (b), or 10% (c) of liposomes were present in blood. Results are expressed as the mean percentages (n 5 6 per time point
per treatment) of clearance 6 standard deviations in mice treated with liposomes (u) or buffer (1). p, P # 0.001 versus buffer-treated mice.
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RESULTS
Determination of the time points at which 50 or 10% of
injected empty liposomes are present in blood of mice. The
three types of empty liposomes showed different blood circu-
lation times (Fig. 1). At 1 min after liposome administration,
more than 90% of the liposome dose was present in blood for
all three liposome types. At the high dose of 400 mmol of
lipid/kg, 50% of the liposome dose was present in blood at 50
min for LIP A, at 4 h for LIP B, and at 16 h for LIP C; 10% of
the liposome dose was present in blood at 110 min for LIP A,
at 40 h for LIP B, and at 48 h for LIP C. At the dose of 80 mmol
of lipid/kg, for LIP A 50% of the dose was present in blood at
10 min, and 10% of the dose was present at 30 min.
Effect of i.v. administration of empty liposomes on carbon
clearance from blood in mice. Clearance of carbon from blood
in mice after single-dose administration of either LIP A, LIP B,
or LIP C at a dose of 400 mmol of lipid/kg is shown in Fig. 2.
Due to administration of LIP A (classical liposomes) at the
high dose of 400 mmol of lipid/kg, the carbon clearance within
9 min was significantly reduced (P # 0.001) at all time points
measured, being 46, 58, and 47% at 1, 50, and 110 min after
liposome administration, respectively, whereas in control ani-
mals carbon clearance was 72, 88, and 65% at the same time
intervals, respectively, after buffer administration. In contrast,
when LIP A was administered at the low dose of 80 mmol of
lipid/kg the carbon clearance efficiency was unaffected (data
not shown). Administration of LIP B (placebo-AmBisome) or
LIP C (placebo-Doxil) at the high dose of 400 mmol of lipid/kg
did not result in impaired carbon clearance capacity.
Effect of i.v. administration of empty liposomes on bacterial
clearance from blood in mice. Clearance of K. pneumoniae and
S. aureus from blood in mice after single-dose administration
of either LIP A, LIP B, or LIP C at a dose of 400 mmol of
lipid/kg is shown in Fig. 3 and 4, respectively. In buffer-treated
control mice, an average of 56% of K. pneumoniae bacteria was
cleared within 9 min. Administration of all three types of lipo-
somes at the high dose of 400 mmol of lipid/kg did not affect
the bacterial clearance efficiency at any of the time points.
The clearance of S. aureus within 9 min amounted to an
average of 95% in buffer-treated controls. Again, the bacterial
clearance efficiencies were not different among animals treated
with all three types of empty liposomes, with one exception: at
1 min after administration of LIP B (placebo-AmBisome), the
clearance capacity was slightly but significantly (P # 0.001)
reduced to 80%.
Effect of i.v. administration of AmBisome on bacterial clear-
ance from blood in rats. Clearance of K. pneumoniae from
blood after daily administration of AmBisome, placebo lipo-
somes, or buffer for either 5 or 10 consecutive days is shown in
Fig. 5 and 6, respectively. In buffer-treated control rats, more
than 99% of K. pneumoniae bacteria was cleared within 60 min.
Administration of AmBisome daily at 5 or 10 doses of 5 mg of
AMB/kg each did not affect clearance of K. pneumoniae within
60 or 120 min after inoculation, when determined at 24 or 72 h
after the last dosage.
DISCUSSION
Administration of liposome-based therapeutic agents might
affect the blood clearance capacity of the MPS. In the present
study, the effects of administration of the liposomal carrier
alone (empty liposomes) as well as that of a liposome contain-
ing the potentially toxic agent AMB, AmBisome, were inves-
tigated. Blood clearance capacity was assessed at various time
points after liposome administration, as both during circula-
tion and after uptake by the MPS liposomes might interfere
with the clearance of other particles from blood.
As the classical parameter for determination of the phago-
cytic capacity of the MPS is the clearance of carbon particles
(1, 10, 11), this parameter was also used in the present study.
FIG. 3. Clearance of K. pneumoniae from blood in mice after single-dose administration (i.v.) of empty liposomes at 400 mmol of lipid/kg. For explanations of
symbols and panels, see the legend to Fig. 2.
FIG. 4. Clearance of S. aureus from blood in mice after single-dose administration (i.v.) of empty liposomes at 400 mmol of lipid/kg. For explanations of symbols
and panels, see the legend to Fig. 2.
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In addition, the clearance of bacteria from blood was moni-
tored, as this seems to be a much more relevant parameter
from a clinical point of view. Two clinically relevant bacterial
pathogens, K. pneumoniae and S. aureus, were chosen. For
K. pneumoniae, an inoculum that resulted in a clinically rele-
vant bacterial load in blood (as observed in septicemia) was
used. S. aureus is cleared from the blood much more rapidly
than K. pneumoniae in this strain of mice. In order to obtain
bacterial numbers in blood that could be determined accu-
rately at the indicated time points, a much higher inoculum of
S. aureus was necessary.
The first part of the study focused on the effects of three
types of empty liposomes, differing in blood residence time.
LIP A (classical liposome) is rapidly cleared from the blood
by the phagocytic cells of the MPS, due to its strong negative
charge (PS), low rigidity of the bilayer, and relatively large par-
ticle size. Clearance from blood of LIP B (placebo-AmBisome),
which has a small liposome size and increased rigidity of the
bilayer, is greatly reduced compared to that of classical lipo-
somes. For LIP C (placebo-Doxil), incorporation of PEG-
DSPE results in a hydrophilic PEG coating on the surface of
the liposomes, by which binding of blood proteins is substan-
tially reduced. As a result, prolonged blood residence time of
liposomes is obtained even at low lipid dosages, small particle
size, or low rigidity of the bilayer (26). For LIP A, LIP B, and
LIP C, 50% of the injected dose of liposomes was present in
blood at 50 min, 4 h, and 16 h after administration in mice,
respectively. For that reason, the blood clearance capacity of
the MPS was not measured at fixed time points after liposome
administration but at the time points at which equal amounts
of liposomes, namely, .90, 50, or 10% of the injected dose,
were present in blood.
For classical liposomes, carbon clearance was significantly
reduced at each of the three different time points after admin-
istration of a lipid dose of 400 mmol of lipid/kg. However, bac-
terial clearance was not reduced. This high lipid dose amply
exceeds the lipid doses that are presently used in clinical prac-
tice. Therefore, the blood clearance capacity was also moni-
tored at a more clinically relevant dose of 80 mmol of lipid/kg.
At this relatively low lipid dose, both carbon clearance and
bacterial clearance were not affected. The data obtained clear-
ly demonstrate that the assessment of blood clearance capacity
of the MPS is greatly determined by the type of particle that is
used.
For carbon as well as for bacteria, the blood clearance was
not reduced after administration of empty liposomes repre-
senting the size and lipid composition of AmBisome and Doxil,
respectively. These findings are not surprising as both types of
liposomes are characterized by relatively long circulation half-
lives, due to reduced MPS uptake.
In the second part of the study, we examined whether for
AMB-containing liposome, AmBisome, similar results were ob-
tained. Until now, the safety of AmBisome has been studied
with a focus on infusion-related adverse effects, renal function,
FIG. 5. Effect of AmBisome (n) for 5 consecutive days at 5 mg of AMB/kg z day (equivalent to 50 mmol of lipid/kg z day) on clearance of K. pneumoniae from blood
in rats. Bacterial blood clearance was determined at 24 as well as 72 h after the last injection of liposomes. Controls were treated with placebo liposomes (h) or buffer
(E). Results are expressed as the geometric means of numbers of viable bacteria 6 standard deviations for 10 rats per time point per treatment.
FIG. 6. Effect of AmBisome (n) for 10 consecutive days at 5 mg of AMB/kg z day (equivalent to 50 mmol of lipid/kg z day) on clearance of K. pneumoniae from
blood in rats. For explanations of open symbols, see the legend to Fig. 5.
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and hepatic function (in particular, functioning of hepatocytes)
(16, 17, 19). In the present study, the effect of multiple-dose
administration of AmBisome on the bacterial blood clearance
capacity of the MPS was studied.
AmBisome was evaluated with a clinically relevant dose reg-
imen of 5 mg of AMB/kg z day (15) and was administered daily
during a period of 5 or 10 days, as 10 i.v. injections were max-
imally tolerated by the rats. To measure bacterial clearance
capacity, K. pneumoniae was inoculated, as the clearance of
this highly encapsulated bacterial strain from blood is rather
slow compared to that of other bacterial pathogens. In infec-
tions caused by highly encapsulated bacteria, maximal MPS
function is very important. Bacterial blood clearance capacity
measured over a 120-min period was never impaired, not even
after prolonged treatment with AmBisome.
Prolonged treatment schedules, resembling the clinical set-
ting closely, were applied (15). A total of 5 or 10 daily doses of
AmBisome in rats is expected to result in high levels of AMB,
particularly in the liver and spleen (13, 19, 23). The pattern of
tissue distribution of AMB in animals appears quite similar to
that determined for humans at autopsy (20). From the animal
studies, it is known that the AMB concentrations in liver and
spleen remain high for at least 48 h after the last AmBisome
administration. It is not known whether these high AMB con-
centrations represent liposome-associated AMB or AMB re-
leased after intracellular degradation of AmBisome. Although
intracellular degradation of AmBisome within the phagocytic
cells of the MPS is expected to be slow (22), the exact time
course of AmBisome uptake, degradation, and AMB release is
not known. Therefore, bacterial blood clearance capacity was
determined at different time points during an extended period
after the last liposome administration.
With respect to the other two industrially produced AMB-
lipid formulations, Abelcet (The Liposome Company, Inc.)
and Amphocil (Sequus Pharmaceuticals, Inc.), it is evident that
these have quite different structural and pharmacokinetic char-
acteristics (15). The relatively large structures of Abelcet as
well as the small discoidal particles of Amphocil are rapidly
taken up by the MPS. In particular, for these two AMB-lipid
formulations potential damage to the MPS should be taken
into consideration, and this potential also needs thorough in-
vestigation.
Finally, it is important to note that administration of lipo-
somes may have effects on host defense other than interference
with phagocytic capacity. It has been described, e.g., for lipo-
somal PS, that it can seriously inhibit the effectiveness of
immunomodulating agents acting on macrophages (8). For
AmBisome, reduced infusion-related toxicity was associated
with reduced cytokine levels in plasma compared to those for
conventional AMB (3).
In conclusion, reduction of the blood clearance capacity of
the MPS is a major concern, particularly for immunocompro-
mised patients. The data obtained show that the carbon blood
clearance capacity of the MPS was impaired only at a high lipid
dose of empty classical liposomes. Bacterial blood clearance
capacity was never impaired, not even after prolonged treat-
ment with AmBisome administered in a clinically relevant reg-
imen.
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